Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Identifying REDUCE-IT Trial Eligible Patients in a Structured Coronary Disease Follow-Up Program
Session:
SESSÃO DE COMUNICAÇÕES ORAIS 07 - PRÉMIO FERRER MELHOR COMUNICAÇÃO ORAL EM PREVENÇÃO SECUNDÁRIA
Speaker:
Marta Leite
Congress:
CPC 2025
Topic:
J. Preventive Cardiology
Theme:
28. Risk Factors and Prevention
Subtheme:
28.3 Secondary Prevention
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Marta Leite; Inês Neves; Marta Almeida; André Lobo; Sílvia O. Diaz; Diogo Ferreira; Gualter Santos Silva; Eduardo Vilela; Ricardo Fontes-Carvalho
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Background: </strong>The REDUCE-IT trial demonstrated significant cardiovascular benefits of icosapent ethyl in patients with elevated triglycerides (TG) and optimized statin therapy. Identifying eligible patients in real-world settings is critical to translating these findings into practice and assess the cost-effectiveness of initiating this therapy in patients with high triglycerides levels after an acute coronary syndrome (ACS).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Aim: </strong>This study aimed to evaluate the prevalence of patients meeting REDUCE-IT inclusion criteria within a Structured Coronary-Disease Follow-up Program (SCCC).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Methods:</strong> We conducted a retrospective analysis of patients enrolled in the SCCC program. The SCCC is a structured outpatient program implemented in our center in 2021 for all patients up to 12 months after an ACS and involves regular follow-up consultations focused on optimizing cardiovascular risk factor control. Inclusion criteria for this analysis mirrored those of the REDUCE-IT trial: age ≥45 years, history of cardiovascular disease, TG levels of 135–499 mg/dL measured at any point during the 12-month program, LDL-C levels of 41–199 mg/dL, and stable statin therapy for at least four weeks.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Results: </strong>Among 343 patients managed under the SCCC program, 27 (7.9%) fulfilled the REDUCE-IT inclusion criteria. Eligible patients had a median TG level of 176 mg/dL (IQR: 145–230) and an LDL-C level of 92 mg/dL (IQR: 71–115), with all on stable statin therapy for at least four weeks. These findings highlight a subpopulation that may benefit from icosapent ethyl to further reduce residual cardiovascular risk.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Conclusions:</strong> Approximately 8% of patients within a structured coronary-disease follow-up program met the inclusion criteria for the REDUCE-IT trial. Identifying such patients in real-world clinical settings is essential for targeted intervention and optimizing cardiovascular outcomes. Further studies are warranted to assess the impact of implementing REDUCE-IT findings in this population.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site
